vs
STANDARD BIOTOOLS INC.（LAB）与MODIV INDUSTRIAL, INC.（MDV）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是MODIV INDUSTRIAL, INC.的1.8倍（$19.6M vs $11.1M），MODIV INDUSTRIAL, INC.净利率更高（11.0% vs -177.4%，领先188.4%），MODIV INDUSTRIAL, INC.同比增速更快（-5.6% vs -11.5%），过去两年MODIV INDUSTRIAL, INC.的营收复合增速更高（-3.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
MODIV INDUSTRIAL, INC.是一家总部位于美国的工业地产企业，主要收购、持有并运营北美核心物流集散枢纽的优质工业物业，服务电商履约、制造、第三方物流等领域的租户，满足现代供应链基础设施的增长需求。
LAB vs MDV — 直观对比
营收规模更大
LAB
是对方的1.8倍
$11.1M
营收增速更快
MDV
高出5.9%
-11.5%
净利率更高
MDV
高出188.4%
-177.4%
两年增速更快
MDV
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $11.1M |
| 净利润 | $-34.7M | $1.2M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 45.8% |
| 净利率 | -177.4% | 11.0% |
| 营收同比 | -11.5% | -5.6% |
| 净利润同比 | -28.8% | -22.0% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABMDV
| Q4 25 | — | $11.1M | ||
| Q3 25 | $19.6M | $11.7M | ||
| Q2 25 | $21.8M | $11.8M | ||
| Q1 25 | $40.8M | $11.8M | ||
| Q4 24 | — | $11.7M | ||
| Q3 24 | $22.1M | $11.7M | ||
| Q2 24 | $22.5M | $11.4M | ||
| Q1 24 | $45.5M | $12.0M |
净利润LABMDV
| Q4 25 | — | $1.2M | ||
| Q3 25 | $-34.7M | $1.0M | ||
| Q2 25 | $-33.5M | $-2.0M | ||
| Q1 25 | $-26.0M | $829.0K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | $-26.9M | $-587.0K | ||
| Q2 24 | $-45.7M | $1.3M | ||
| Q1 24 | $-32.2M | $3.7M |
毛利率LABMDV
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABMDV
| Q4 25 | — | 45.8% | ||
| Q3 25 | -168.5% | 41.4% | ||
| Q2 25 | -118.1% | 9.8% | ||
| Q1 25 | -80.8% | 40.2% | ||
| Q4 24 | — | 45.4% | ||
| Q3 24 | -120.9% | 42.0% | ||
| Q2 24 | -134.5% | 44.6% | ||
| Q1 24 | -132.2% | 55.6% |
净利率LABMDV
| Q4 25 | — | 11.0% | ||
| Q3 25 | -177.4% | 9.0% | ||
| Q2 25 | -153.7% | -17.1% | ||
| Q1 25 | -63.8% | 7.0% | ||
| Q4 24 | — | 13.3% | ||
| Q3 24 | -122.0% | -5.0% | ||
| Q2 24 | -203.3% | 11.6% | ||
| Q1 24 | -70.6% | 31.1% |
每股收益（稀释后）LABMDV
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.09 | $0.00 | ||
| Q2 25 | $-0.09 | $-0.32 | ||
| Q1 25 | $-0.07 | $-0.01 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-0.07 | $-0.18 | ||
| Q2 24 | $-0.12 | $0.03 | ||
| Q1 24 | $-0.27 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $14.4M |
| 总债务越低越好 | — | $261.5M |
| 股东权益账面价值 | $399.7M | $162.7M |
| 总资产 | $539.6M | $476.5M |
| 负债/权益比越低杠杆越低 | — | 1.61× |
8季度趋势，按日历期对齐
现金及短期投资LABMDV
| Q4 25 | — | $14.4M | ||
| Q3 25 | $129.4M | $8.3M | ||
| Q2 25 | $158.6M | $5.8M | ||
| Q1 25 | $150.9M | $6.2M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $210.6M | $6.8M | ||
| Q2 24 | $269.8M | $18.9M | ||
| Q1 24 | $287.1M | $18.4M |
总债务LABMDV
| Q4 25 | — | $261.5M | ||
| Q3 25 | — | $279.7M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $279.7M | ||
| Q4 24 | — | $279.8M | ||
| Q3 24 | $55.2M | $279.7M | ||
| Q2 24 | $55.1M | $279.7M | ||
| Q1 24 | $55.0M | $279.6M |
股东权益LABMDV
| Q4 25 | — | $162.7M | ||
| Q3 25 | $399.7M | $164.8M | ||
| Q2 25 | $424.5M | $165.6M | ||
| Q1 25 | $454.6M | $171.1M | ||
| Q4 24 | — | $190.1M | ||
| Q3 24 | $489.3M | $186.3M | ||
| Q2 24 | $510.3M | $187.0M | ||
| Q1 24 | $577.3M | $188.0M |
总资产LABMDV
| Q4 25 | — | $476.5M | ||
| Q3 25 | $539.6M | $499.6M | ||
| Q2 25 | $557.0M | $498.9M | ||
| Q1 25 | $579.6M | $506.8M | ||
| Q4 24 | — | $507.8M | ||
| Q3 24 | $681.5M | $507.4M | ||
| Q2 24 | $708.7M | $519.5M | ||
| Q1 24 | $777.7M | $522.5M |
负债/权益比LABMDV
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | 0.11× | 1.50× | ||
| Q2 24 | 0.11× | 1.50× | ||
| Q1 24 | 0.10× | 1.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | 12.34× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABMDV
| Q4 25 | — | $15.0M | ||
| Q3 25 | $-22.2M | $4.1M | ||
| Q2 25 | $-20.7M | $3.9M | ||
| Q1 25 | $-30.3M | $3.0M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $-27.9M | $5.1M | ||
| Q2 24 | $-39.0M | $4.7M | ||
| Q1 24 | $-62.5M | $3.0M |
自由现金流LABMDV
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABMDV
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABMDV
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
现金转化率LABMDV
| Q4 25 | — | 12.34× | ||
| Q3 25 | — | 3.95× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.68× | ||
| Q4 24 | — | 11.72× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | — | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MDV
暂无分部数据
